Abstract: Personal care and household care compositions comprising a conditioner and rheology modifier based on a cationic galactomannan or cationic xyloglucan having cationic degree of substitution comprised between 0.01 and 3, free from (3-chloro-2-hydroxypropyl)trimethyl ammonium chloride and free from (2,3-epoxypropyl) trimethyl ammonium chloride.

Abstract: Method for inhibiting the swelling and the dispersion of shales in the treatment of subterranean shale formations comprising the use of a cationic tamarind gum and fluids for the treatment of subterranean shale formations comprising a cationic tamarind gum.

Abstract: Personal care and household care compositions comprising a conditioner and rheology modifier based on a cationic galactomannan or cationic xyloglucan having cationic degree of substitution comprised between 0.01 and 3, free from (3-chloro-2-hydroxypropyl)trimethyl ammonium chloride and free from (2,3-epoxypropyl) trimethyl ammonium chloride.

Abstract: Personal care and household care compositions comprising a conditioner and rheology modifier based on a cationic galactomannan or cationic xyloglucan having cationic degree of substitution comprised between 0.01 and 3, free from (3-chloro-2-hydroxypropyl)trimethyl ammonium chloride and free from (2,3-epoxypropyl)trimethyl ammonium chloride.

Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

Abstract: Method for inhibiting the swelling and the dispersion of shales in the treatment of subterranean shale formations comprising the use of a cationic tamarind gum and fluids for the treatment of subterranean shale formations comprising a cationic tamarind gum.

Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

Abstract: An aqueous adjuvant concentrate can be prepared using a formulation including: a. from about 15 to about 45% by weight of a potassium salt chosen among di-potassium phosphate, potassium sulfate, potassium nitrate, tri-potassium citrate, potassium salts of ethylenediaminetetraacetic acid and mixture thereof; b. from about 0.5 to about 6% by weight of at least one surfactant and c. from about 3 to about 9% by weight of a hydroxypropyl tamarind gum; wherein a, b, and c are dissolved into the aqueous adjuvant. The aqueous adjuvant can include other compounds such as ah herbicide.

Abstract: The present disclosure relates to a method of treating a portion of a subterranean formation comprising the use of an aqueous fracturing fluid containing a fast dissolving and easily dispersible unpunfied polygalactomannan ether.

Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

Abstract: Spray drift may be reduced during spray applications. Spray drift during the application of a pesticidal or crop protection spray tank solution may be reduced by mixing the pesticidal or crop protection spray tank solution with a drift control formulation containing a maltodextrin and a C12-C22 mono- or di-carboxylic acid or a salt thereof.

Abstract: An aqueous adjuvant concentrate can be prepared using a formulation including: a. from about 15 to about 45% by weight of a potassium salt chosen among di-potassium phosphate, potassium sulfate, potassium nitrate, tri-potassium citrate, potassium salts of ethylenediaminetetraacetic acid and mixture thereof; b. from about 0.5 to about 6% by weight of at least one surfactant and c. from about 3 to about 9% by weight of a hydroxypropyl tamarind gum wherein a, b, and c are dissolved into the aqueous adjuvant. The aqueous adjuvant can include other compounds such as ah herbicide.

Abstract: Personal care and household care compositions comprising a conditioner and rheology modifier based on a cationic galactomannan or cationic xyloglucan having cationic degree of substitution comprised between 0.01 and 3, free from (3-chloro-2-hydroxypropyl)trimethyl ammonium chloride and free from (2,3-epoxypropyl)trimethyl ammonium chloride.

Abstract: The present invention relates to a process for the preparation of diluted agrochemical spray formations with improved drift control comprising the addition of a hydroxypropyl tamarind as drift control agent.

Abstract: Compounds of formula (I) described herein are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

Abstract: Compounds of formula (I) described herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

Abstract: Compounds having a benzhydryl structure represented by formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for treating diseases of the respiratory tract.

Abstract: Compounds of formula (I) defined herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract characterized by airway obstruction.

Abstract: Compounds having a benzhydryl structure represented by formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for treating diseases of the respiratory tract.